AU Patent

AU2021210987A1 — Protein-antiviral compound conjugates

Assigned to Regeneron Pharmaceuticals Inc · Expires 2022-08-04 · 4y expired

What this patent protects

Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with influenza, including VX-787 and derivatives thereof, baloxavir and derivatives thereof, and baloxavir marboxil and derivatives thereof, and protein (e.g., antibody…

USPTO Abstract

Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with influenza, including VX-787 and derivatives thereof, baloxavir and derivatives thereof, and baloxavir marboxil and derivatives thereof, and protein (e.g., antibody) drug conjugates thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021210987A1
Jurisdiction
AU
Classification
—
Expires
2022-08-04
Drug substance claim
No
Drug product claim
No
Assignee
Regeneron Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.